MRC Call for Capital Funding to Support Regenerative Medicine Research

By | Uncategorized

The Medical Research Council (MRC) is announcing an investment of £20M for capital only funding which will support research addressing the key translational bottlenecks identified through the Strategy for UK Regenerative Medicine. It is envisaged that this funding will complement recent strategic investments, including the UK Regenerative Medicine Platform. Building on existing institutional strengths, successful bids will provide or enhance national capabilities to meet the challenges identified in the UK strategy.

Further information on the call and details of how to submit an application are available on the MRC Call for proposals page

£20m boost for UK regenerative medicine

By | Uncategorized

The Medical Research Council (MRC) and British Heart Foundation (BHF) today announced £20m of funding to boost the development of regenerative medicine therapies.

The awards will help UK scientists overcome some of the barriers to transforming laboratory discoveries in this emerging field into clinical applications that will address a spectrum of chronic and untreatable medical conditions.

 

Around £13m will be awarded through the first stage of the UK Regenerative Medicine Platform (UKRMP), which is jointly funded by the MRC, the Biotechnology and Biological Sciences Research Council and Engineering and Physical Sciences Research Council. This will establish three research ‘hubs’ that bring together teams of scientists with skills and expertise in a range of disciplines to tackle the grand challenges in regenerative medicine.

The BHF has pledged a further £7.5 million to fund scientists at three new dedicated research centres, based at prestigious universities across the UK. The three BHF Centres for Regenerative Medicine, funded by the Mending Broken Hearts Appeal, will specialise in looking for new treatments to repair the damage caused by a heart attack.

Regenerative medicine is a relatively new field of science which uses a range of biological tools to repair or replace damaged tissue. This field has the potential to transform medical care by providing treatments for incurable conditions such as heart disease, Parkinson’s disease, blindness and liver failure.

Though there have been many advances in laboratory studies of stem cells and other regenerative approaches, to date relatively few therapies have made it to human trials. This is largely because cell-based therapies are far more complex than traditional small molecule drugs, and require further research and new approaches to make sure they are safe, effective and can be produced in the volumes required to treat large numbers of patients.

The UKRMP hubs will work together, with the BHF centres, to address these issues and develop the tools, technologies and engineering solutions needed to take regenerative therapies into the clinic. The hubs will each focus on a specific theme:

  • Engineering and exploiting the stem cell niche (microenvironment), led by the MRC Centre for Regenerative Medicine at the University of Edinburgh.
  • Safety and efficacy of cell therapies, led by the MRC Centre for Drug Safety Science at the University of Liverpool.
  • Acellular (biomaterial) approaches and targeted drug delivery for tissue regeneration, led by the University of Nottingham.

A further hub looking at the development of high quality, stable stem cell lines and their direction towards specific tissue types to support manufacture for clinical application is expected to be established later in the year. In total, the UKRMP aims to invest £25m by March 2014.

Minister for Universities and Science David Willetts said:

“Regenerative medicine is a hugely promising area of science, which is why it featured in our Strategy for UK Life Sciences and was identified as one of the eight great technologies. This investment will help take excellent basic research through to clinical application, benefitting patients and driving growth.”

Dr Rob Buckle from the MRC, who is Director of the UKRMP, said:

“Today’s investment from the Research Councils and British Heart Foundation will help the UK move closer to realising the full potential of regenerative medicine to transform the lives of patients. By bringing together experts from a broad range of scientific disciplines the hubs will help forge links between academia and industry to drive innovation, promote clinical and commercial development of therapies and help grow a vibrant UK bioindustry in this area.”

Professor Peter Weissberg, Medical Director at the BHF, said:

“We’re excited by the transformational impact these centres could have on science aimed at repairing heart damage. By working with the UK Regenerative Medicine Platform’s hubs, our BHF Centres of Regenerative Medicine will turn groundbreaking research into real benefits for people with heart failure. We have committed to spending £7.5m on these centres over the coming years from our Mending Broken Hearts Appeal, but this depends crucially on continued support from the public. You can help by supporting our Mending Broken Hearts Appeal.”

The MRC is currently inviting expressions of interest for capital funding to support regenerative medicine research, which will be used to determine the precise scope of a full call for proposals to be announced in April/May 2013. More information can be found here.

For more information, contact Hannah Isom in the MRC press office on 0207 395 2345 or email press.office@headoffice.mrc.ac.uk

MRC Call for Expressions of Interest for capital funding to support regenerative medicine research

By | Uncategorized

The Medical Research Council (MRC) have launched a call for Expressions of Interest to support regenerative medicine research.  The purpose of the Call for Expression of Interest (EoI) is to gauge the range of interest for capital funding to support regenerative medicine research.

The EoIs solicited will be used to determine the precise scope of a full call for proposals to be announced in April/May 2013, taking into account the nature and scale of the investments proposed, and their likely impact in relation to the scientific opportunities and capabilities presented in the context of the UK’s strategic needs in this area.

Further information on the call and details of how to submit an EoI are available on the MRC Call for proposals page

California-UK collaborative opportunity in translational stem cell research.

By | Uncategorized

The Medical Research Council (MRC) has agreed to partner the Californian Institute of Regenerative Medicine (CIRM) in its Disease Team Therapy Development Awards III Request for Applications (RFA 13-01), which aims to progress late preclinical and early clinical translational stem cell research.

Stem cell research offers enormous potential for the development of novel therapies, derived from or targeting stem cells, for the treatment of disease and serious injury. The application of stem cell research to clinical problems has matured to the stage that stem cell-based therapies are now poised to progress into clinical testing. The aim of RFA 13‑01 is to accelerate clinical proof of concept for potential therapies based on stem cell research through the completion of Phase I and/or Phase 2 clinical studies.

The MRC is calling for proposals from UK groups active in the late preclinical and early clinical domain that can link to Californian research teams, to establish high quality, multidisciplinary translational research programmes. Funded programmes will be milestone-driven and have the maturity and critical mass to complete early clinical testing within the four-year period of support. Further information on the initiative and details of how to submit an application is available on the MRC Calls for Proposals page

Cell Therapy Catapult publishes UK clinical trials database

By | Uncategorized

The Cell Therapy Catapult, which is focssed on the development of the UK cell therapy industry to increase the nation’s health and wealth, has published its database of ongoing clinical trials in this area in the UK.

It details 21 studies, and will be used by the organisation to identify potential programmes for develpment or partnership, as well providing a key indication of progress in the UK cell therapy industry.  The database will be updated regularly and input from the cell therapy community is welcomed in order to ensure it remains comprehensive and accurate.  To read more follow this link.

MRC-TSB iPSC Grand Challenge Workshop Report

By | Uncategorized

The MRC and TSB held an iPSC Grand Challenge Workshop on the 1st August 2012 in Birmingham.

The workshop was attended by delegates from across the UK iPSC research landscape, who met to discuss the emerging opportunities and challenges in iPSC research and identify how the UK research community could best work together to progress the field.   A report form the workshop is available to download  here.

Opportunity for joint EPSRC/MRC Centres for Doctoral Training

By | Uncategorized

MRC is collaborating with EPSRC on its new Centres for Doctoral Training to start in 2014, with the aim of developing new cadres of early-career researchers trained in highly multidisciplinary research and training settings.

More details of the call, which is due to open in February 2013, will be available in early 2013. Currently, the following joint priority areas have been identified, for which MRC/EPSRC co-funding may be available if appropriate:

 

For more details of the call, as well as a timetable, please visit EPSRC’s website

Wellcome Trust and MRC invest £13m to create a new national stem cell resource

By | Uncategorized

The Wellcome Trust and Medical Research Council (MRC) today announced a £12.75 million initiative to create a catalogue of high-quality adult stem cells, so-called induced pluripotent stem cells (iPS cells).

The initiative will provide a knowledge-base to underpin the use of such cells in studying the effects of our genes on health and disease and lay the foundations to create a new iPS cell bank, providing a world-class resource for UK researchers.

 

Read more;